Covi-Pantel . NZ Trader Release, page-1127

Hi Pickem,

There is no point looking at difloria immitis ( Australian version Heart worm Canines) nor Brugia Malayi ( OS version of heart worm ) that one also transfers to humans as Lympathic Filaraisis . Studies show our drug doesn’t work.

MPL in relation to parasites is a positive allosteric modulator of DEG3 and ACR23. In other words it interferes with the larvae stage of the parasite. The parasites that are susceptible to MPL must have sub units of the RNA genome of DEG etc.

Covid 19 is a virus , our compound interferes with the CDK4 protein , which stops the replication phase.

I have looked at many parasitic diseases that have DEG3 /ACR 23 in their make up and cross reference.

In relation to human development disease I have looked at mTOR inhibition and cross reference diseases that cause increased mTOR values.

Takes weeks, there is many false trails, but some positive outcomes.

This is all retro analysis , there is a lack of studies in some conditions. MPL is a new repurposed compound. Everyone is starting at the ground floor.

PAA is also learning as well. It’s just the public can’t see their in depth reports due to the possibility of patent pilferage by unknowns.

I am trying to fill that void.